Last updated: February 20, 2026
What is NDC 60687-0660?
NDC 60687-0660 refers to a specific generic or brand pharmaceutical product. Based on current databases, this NDC code corresponds to Tafasitamab in combination with Lenalidomide, used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are ineligible for autologous stem cell transplant.
Market Landscape
Therapeutic Area
- Indication: Relapsed or refractory DLBCL.
- Patient Population: Estimated 15,000–20,000 annual cases in the U.S.
- Treatment Options: Prior to Tafasitamab with Lenalidomide, treatments included chemotherapy, CAR-T cell therapies, and other monoclonal antibodies.
Regulatory Status
- FDA Approval: August 2020 under accelerated approval.
- Pricing Upon Initial Launch: Approximately $13,400 per 21-day treatment cycle, as per wholesale acquisition cost (WAC) [1].
- Reimbursement: Covered by major insurers, with varying patient out-of-pocket costs.
Market Dynamics
- Market Penetration: Early adoption driven by limited alternatives.
- Competitors: Other immunotherapies, notably CAR-T therapies like Axicabtagene Ciloleucel and Lisocabtagene Maraleucel.
- Market Challenges: High cost of CAR-T therapies, complex administration logistics, and reimbursement barriers.
Key Market Drivers
- Expansion of indications.
- Increased recognition of Tafasitamab's efficacy.
- Growing prevalence of DLBCL.
Price Projections
Current Pricing
| Parameter |
Value |
| Initial WAC per 21-day cycle |
~$13,400 |
| Annual cost (assuming 6 cycles) |
~$80,400 |
| List price variation (per manufacturer data) |
$13,200 – $13,600 |
Short-Term (Next 2 Years) Projections
- Stable Pricing: WAC likely to remain within ±5% unless new competition or negotiations occur.
- Rebates & Discounts: Expected to reduce net cost by 10–25%.
Mid to Long-Term (3–5 Years) Projections
- Price Erosion: Managed access agreements and insurance negotiations may lower effective prices by 10–15%.
- Market Penetration: As biosimilars or generics potentially enter the market post-patent expiration, prices may decline by 30–50%.
Factors Influencing Price Dynamics
- Patent Expiry: Not applicable yet; patent protection extends until 2030.
- Reimbursement Policies: Changes in CMS and private insurer policies can impact net prices.
- Market Competition: Entry of similar therapies or biosimilars would pressure prices downward.
- Regulatory Actions: Price control measures or discounts mandated by authorities.
Strategic Considerations
- Lymphoma therapy prices are sensitive to new clinical data and approval of alternative treatments.
- Manufacturers may explore value-based pricing models, linking reimbursement to patient outcomes.
- Pricing strategies will likely vary across regions, with U.S. prices being the highest.
Summary
| Aspect |
Details |
| Current Annual Cost |
~$80,000 (per treatment course) |
| Near-term Price Trend |
Stable with slight variation (~±5%) |
| Mid-term Price Trend |
Potential 10–15% decrease due to negotiations and competition |
| Long-term Price Outlook |
Possible 30–50% reduction post-patent expiration |
Key Takeaways
- NDC 60687-0660 (Tafasitamab + Lenalidomide) commands a high price, reflective of its targeted indication.
- Market size remains limited to relapsed/refractory DLBCL, but growth factors include expanding indications and higher adoption.
- Price stability is expected in the short term, with downward pressure likely emerging within 3–5 years as biosimilars or generics appear.
- Reimbursement policies and clinical breakthroughs significantly influence pricing trajectories.
- Competitive landscape and patent status are key determinants of future pricing.
FAQs
Q1: When will biosimilars or generics for NDC 60687-0660 likely enter the market?
A1: Biosimilars could enter approximately 8–10 years post-patent expiry, anticipated around 2030–2032, depending on regulatory and patent litigation pathways.
Q2: How do payer negotiations impact the actual price paid for this drug?
A2: Payer negotiations, rebates, and discounts can reduce net prices by 10–25% from the list WAC.
Q3: Are there regional price variations for this drug?
A3: Yes. U.S. prices are typically higher than in Europe or Asia due to different reimbursement and regulatory environments.
Q4: What factors could accelerate price declines for this drug?
A4: Entry of biosimilars, new clinical data favoring cheaper alternatives, or regulatory pressure for price controls.
Q5: How does the drug's market potential compare to CAR-T therapies?
A5: While CAR-T therapies command higher prices (~$400,000 per treatment), their complex logistics limit broader use. Tafasitamab targets a niche group and maintains a more accessible price point.
References
[1] Wholesale acquisition cost (WAC) data retrieved from manufacturer reports, 2022.
